Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

ReNeuron Group plc (AIM: RENE),a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2018.

ReNeuron Group
Posted on: 12 Jul 18

Operational Highlights

 

  • CTX stem cell therapy candidate for stroke disability:  

-          Long term data from Phase II clinical trial presented, showing sustained improvements in motor function and reduced levels of disability and dependence

-          IND application approved by FDA to commence a Phase IIb, placebo-controlled clinical trial in the US

-          Patient recruitment expected to commence shortly leading to top-line data at the end of 2019

 

  • hRPC stem cell therapy candidate for retinal diseases:

-          Four patient cohorts treated in ongoing US Phase I/II clinical trial in retinitis pigmentosa (RP)

-          Phase I/II study to be expanded to target patients with less-impaired vision

-          Top line Phase I/II data now expected in mid-2019

-          Phase II study planned in cone-rod dystrophy patients, to run in parallel with planned Phase IIb study in RP

 

  • Exosome nanomedicine platform:

-          Positive pre-clinical data with ExoPr0 exosome therapy candidate demonstrates potential of ExoPr0 to target multiple diseases

-          Initial clinical trial application planned for 2019 in oncology

 

  • US office established in Boston, reflecting the Company’s increasing clinical activity in the US

 

  • Increased business development activity in the period due to third party interest in Company’s core therapeutic programmes

-          Active discussions ongoing with a number of commercial third parties

 

  • Increased collaborative work in the period to exploit technology platforms beyond core therapeutic programmes

 

Financial Highlights

 

  • Loss for the period of £17.6 million (2017: loss of £15.6 million)

 

  • Cash used in operating activities of £14.9 million (2017: £12.6 million)

 

  • Cash, cash equivalents and bank deposits at 31 March 2018 of £37.4 million (31 March 2017: £53.1 million)

 

  • 1 for 100 Share Capital Reorganisation completed in the period

 

  • Three further government grants awarded in the period and post-period end, providing funding towards £5.0 million of collaborative work programmes across the Company’s therapeutic development programmes

 

Post-period end

 

  • Further positive pre-clinical data demonstrates that ExoPr0 exosome therapy candidate significantly reduces tumour volume in a variety of in vivo models of cancer

 

  • Exclusivity agreement signed with US-based specialty pharmaceutical company regarding potential out-licensing of hRPC technology platform and therapeutic programmes

 

Commenting on the results, Olav Hellebø, Chief Executive Officer, said:

 

“During the period, our therapeutic development programmes have continued to progress well.  The regulatory approval from FDA to commence a Phase IIb clinical trial in the US with our CTX cell therapy candidate for stroke disability was a significant milestone for ReNeuron and we look forward to dosing the first patient in this study.  Dosing has progressed during the period in our ongoing US Phase I/II study with our hRPC cell therapy candidate for retinitis pigmentosa and we have continued to generate and present encouraging pre-clinical data with our ExoPr0exosome therapy candidate in oncology. 

 

“We now have a physical presence in Boston, US, one of the world’s leading biotechnology hubs, where our new US office reflects ReNeuron’s increasing clinical activity in this territory.  Further, our cell-based technologies and therapeutic programmes have attracted the interest of a number of commercial third parties, leading, initially, to yesterday’s separate announcement of an exclusivity agreement with a US specialty pharmaceutical company regarding our hRPC retinal stem cell technology and therapeutic programmes.  We hope to be able to conclude a definitive agreement with this company later this year.

 

“Our cash position remains robust and we are positioned to deliver significant clinical milestones across our therapeutic programmes during each of the next three years.”

 

Analyst meeting and webcast:

 

A meeting for analysts will be held at 10.00am today at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.

 

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am:

 

https://buchanan.enablecloud.co.uk/index.php?entryPoint=campaign_trackerv2&track=5ca659c6-8595-11e8-9eb1-18a905591bc2&identifier=d6315a30-8599-11e8-ac22-001a4bbe9414

 

For further details please contact Buchanan on 020 7466 5000.

 

A recording of the webcast will be made available on ReNeuron's website, www.reneuron.com

 

 Enquiries:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer

 

Michael Hunt, Chief Financial Officer

 

 

Buchanan

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 

 

 

Stifel Nicolaus Europe Limited

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

+44 (0) 20 7710 7600

N+1 Singer Advisory LLP

Mark Taylor (Joint Broker)

 

+44 (0) 20 7496 3000

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 12/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.